Amber Rexwinkle is a pharmacist who is specialized in Oncology in Houston, Texas. Patients can reach her at 1515 Holcombe Blvd, Unit 0377, Houston or contact her on 713-563-6655. Active license number of Amber Rexwinkle is 46444 for Oncology in Texas. Amber Rexwinkle is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Amber Rexwinkle speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Amber Rexwinkle
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Female
Location:
1515 Holcombe Blvd, Unit 0377, Houston, Texas, 77030-4000
Phone:
713-563-6655
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Amber Rexwinkle are as mentioned below.
NPI Number:
1356794978
NPI Enumeration Date:
19 Jul, 2016
NPI Last Update On:
19 Jul, 2016
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Amber Rexwinkle are as mentioned below.
Specialization
License Number
State
Status
Oncology
46444
Texas
Primary
Oncology
RP441008
Pennsylvania
Secondary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1423 Shearn St, Houston, Texas
Zip:
77007-4147
Phone Number:
--
Fax Number:
--
Patients can reach Amber Rexwinkle at 1515 Holcombe Blvd, Unit 0377, Houston, Texas or can call on phone at 713-563-6655.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 May, 2024.